Online inquiry

IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12351MR)

This product GTTS-WQ12351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13150MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ4538MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9243MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ6181MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ9468MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ4900MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ3362MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ11567MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW